Compare Natera Inc. Common Stock (NTRA) vs TC Energy Corporation Common Stock (TRP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs TC Energy Corporation Common Stock — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while TC Energy Corporation Common Stock trades at $61.12 (market cap $63.97B). The key difference: Natera Inc. Common Stock and TC Energy Corporation Common Stock are close in size by market cap, and TC Energy Corporation Common Stock pays a 4.02% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and TC Energy Corporation Common Stock for 6 Days on average.
| NTRA | TRP | |
|---|---|---|
Market Cap | $57.03B | $63.97B |
Volume | 1,131,157 | 3,039,280 |
Sector | Health | Energy |
52-Week High | $425.64 | $70.91 |
52-Week Low | $179.42 | $49.79 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $56.18B | $108.73B |
Dividend Yield | — | 4.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
TRP trades at $61.55, up 1.63% with a bullish technical signal despite mixed moving averages. The company shows solid fundamentals with $15.24B revenue, 22.91% net margin, and consistent EBITDA growth. Recent developments include Coastal GasLink Phase 2 expansion approval and a $400M pipeline divestiture, positioning for long-term natural gas demand growth. Analyst consensus is strongly bullish with a $85 price target representing 38% upside potential.
TRP presents a compelling investment case with strong profitability, strategic growth initiatives, and overwhelming analyst support. Key risks include execution challenges on major projects, interest rate sensitivity, and energy market volatility. The stock's current valuation at 25x P/E appears reasonable given growth prospects and 4.3% dividend yield, though technical indicators suggest near-term consolidation may occur.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About TC Energy Corporation Common Stock
TC Energy operates energy infrastructure, including natural gas pipelines and storage systems. Its assets transport energy across North America.
Read more on TRP →
